KR101145190B1 - 사람 파필로마바이러스 폴리펩타이드 및 면역원성 조성물 - Google Patents

사람 파필로마바이러스 폴리펩타이드 및 면역원성 조성물 Download PDF

Info

Publication number
KR101145190B1
KR101145190B1 KR1020057005780A KR20057005780A KR101145190B1 KR 101145190 B1 KR101145190 B1 KR 101145190B1 KR 1020057005780 A KR1020057005780 A KR 1020057005780A KR 20057005780 A KR20057005780 A KR 20057005780A KR 101145190 B1 KR101145190 B1 KR 101145190B1
Authority
KR
South Korea
Prior art keywords
leu
arg
cys
glu
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020057005780A
Other languages
English (en)
Korean (ko)
Other versions
KR20050053732A (ko
Inventor
래리 스미스
마리아 크리스티나 카세티
수잔 피 맥엘리니
제프리 케이 풀렌
Original Assignee
와이어쓰 홀딩스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 와이어쓰 홀딩스 코포레이션 filed Critical 와이어쓰 홀딩스 코포레이션
Publication of KR20050053732A publication Critical patent/KR20050053732A/ko
Application granted granted Critical
Publication of KR101145190B1 publication Critical patent/KR101145190B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
KR1020057005780A 2002-10-03 2003-10-02 사람 파필로마바이러스 폴리펩타이드 및 면역원성 조성물 Expired - Lifetime KR101145190B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41592902P 2002-10-03 2002-10-03
US60/415,929 2002-10-03
PCT/US2003/031726 WO2004030636A2 (en) 2002-10-03 2003-10-02 Human papillomavirus polypeptides and immunogenic compositions

Publications (2)

Publication Number Publication Date
KR20050053732A KR20050053732A (ko) 2005-06-08
KR101145190B1 true KR101145190B1 (ko) 2012-05-14

Family

ID=32069921

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057005780A Expired - Lifetime KR101145190B1 (ko) 2002-10-03 2003-10-02 사람 파필로마바이러스 폴리펩타이드 및 면역원성 조성물

Country Status (16)

Country Link
US (2) US7223408B2 (enExample)
EP (1) EP1553966B1 (enExample)
JP (2) JP4755422B2 (enExample)
KR (1) KR101145190B1 (enExample)
CN (1) CN1720060B (enExample)
AU (1) AU2003282731B2 (enExample)
BR (1) BR0314529A (enExample)
CA (1) CA2499837C (enExample)
CO (1) CO5700784A2 (enExample)
DK (1) DK1553966T3 (enExample)
ES (1) ES2391451T3 (enExample)
MX (1) MXPA05003395A (enExample)
NZ (1) NZ556544A (enExample)
PT (1) PT1553966E (enExample)
WO (1) WO2004030636A2 (enExample)
ZA (1) ZA200502618B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
DK1363938T3 (en) 2000-08-03 2014-03-24 Univ Johns Hopkins Molecular vaccine that connects an endoplasmic reticulum-chaperonepolypeptid with an antigen
PT1553966E (pt) * 2002-10-03 2012-10-22 Wyeth Corp Péptidos de fusão que compreendem os polipéptidos e7 e e6 do vírus do papiloma humano e as composições imunogénicas dos mesmos
WO2004098526A2 (en) 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
US8399610B2 (en) * 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
GB0417430D0 (en) * 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
JP4474264B2 (ja) 2004-08-20 2010-06-02 生寶生物科技股▲ふん▼有限公司 子宮頸癌抑制の融合蛋白
US7354719B2 (en) 2004-12-08 2008-04-08 Gen-Probe Incorporated Detection of nucleic acids from multiple types of human papillomaviruses
AU2005322960A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
AU2006205638A1 (en) 2005-01-14 2006-07-20 The Regents Of The University Of Michigan Systems, methods, and compositions for detection of human papilloma virus in biological samples
EP1846026A4 (en) * 2005-01-26 2008-07-02 Univ Johns Hopkins ANTIBODY DNA VACCINE WITH PLASMIDES FOR CODING A MUTATED ONCOPROTEIN ANTIGEN AND CALRETICULIN
JP5345053B2 (ja) * 2006-04-19 2013-11-20 浦項工科大學校 産學協力團 子宮頸癌の予防及び治療のためのヒトパピローマウイルスポリペプチドと免疫増強剤を含む組成物
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
WO2008150577A1 (en) * 2007-06-01 2008-12-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine for the prevention of breast cancer relapse
US20090117123A1 (en) * 2007-11-02 2009-05-07 National Health Research Institutes Immunopeptides of hpv e6 and e7 proteins
US20120121715A1 (en) * 2008-01-02 2012-05-17 National Taiwan University DNA Vaccine Comprising IL-6-Encoding DNA Construct and Applications Thereof
EP2335730A1 (en) * 2009-12-18 2011-06-22 Deutsches Krebsforschungszentrum Fusion polypeptides and their use for prevention and treatment of cancer
KR101197627B1 (ko) 2010-01-18 2012-11-07 (주)레퍼런스바이오랩 Ｈｐｖ 감염과 관련된 암의 치료용 조성물
JP5965846B2 (ja) 2010-02-16 2016-08-10 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 近縁のヒトパピローマウイルス（ｈｐｖ）の血清型を検出するためのアッセイ
US9376727B2 (en) 2010-05-25 2016-06-28 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically truncated probes
PL2604629T3 (pl) 2010-08-13 2018-08-31 Genexine, Inc. Kompozycja do zapobiegania lub leczenia raka szyjki macicy ze wzmacniaczem odporności przeciwko wirusowi brodawczaka ludzkiego
CA3161127A1 (en) * 2011-10-12 2013-04-18 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
TR201908199T4 (tr) * 2011-12-21 2019-06-21 Vaccibody As HPV'ye karşı aşılar.
CN104159607A (zh) * 2012-01-24 2014-11-19 桑福德研究院/南达科他大学 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸
CN103288931B (zh) * 2012-02-24 2015-05-27 宋硕 人类乳头瘤病毒免疫原性多肽、其制备方法及应用
CA2898522A1 (en) * 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Improved vaccines for human papilloma virus and methods for using the same
BR112015022367B1 (pt) * 2013-03-15 2021-06-22 The Trustees Of The University Of Pennsylvania Vacina, molécula de ácido nucleico, e, molécula de aminoácido
JP2017525760A (ja) 2014-08-15 2017-09-07 ジェネクシン・インコーポレイテッドＧｅｎｅｘｉｎｅ， Ｉｎｃ． 子宮頸癌を処置する方法
JP5973007B2 (ja) * 2015-01-30 2016-08-17 ジェネクサイン・インコーポレーテッド ヒトパピローマウイルス変形体及び免疫増強剤を含む子宮頸癌の予防または治療用組成物
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
CN107921117B (zh) * 2015-06-10 2022-06-07 霍欧奇帕生物科技有限公司 Hpv疫苗
WO2017060360A1 (en) * 2015-10-06 2017-04-13 Invectys Polyepitope constructs for use in immunotherapy
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
WO2017181148A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
CN112574317B (zh) * 2017-01-24 2023-12-05 南京益康生物医药有限公司 一种重组蛋白及药物组合物与应用
AU2018247958A1 (en) * 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors
EP3461497A1 (en) * 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Viral antigens
WO2021026335A1 (en) * 2019-08-08 2021-02-11 The Trustees Of Indiana University Methods for identifying and treating urinary tract infections
PH12022552820A1 (en) 2020-04-24 2024-03-25 Genexine Inc Method for treating cervical cancer
CN114478712B (zh) * 2022-03-29 2022-09-23 深圳吉诺因生物科技有限公司 Hpv抗原表位及其鉴定方法、应用
WO2024145863A1 (en) * 2023-01-05 2024-07-11 Virogin Biotech (Shanghai) Ltd. A NOVEL mRNA VACCINE FOR THE TREATMENT AND PREVENTION OF HPV-ASSOCIATED LESIONS AND TUMORS
CN117925916A (zh) * 2024-03-11 2024-04-26 广州市金域转化医学研究院有限公司 Hpv dna的e6基因在制备浸润性宫颈癌诊断产品中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004557A (en) * 1994-12-20 1999-12-21 Csl Limited Variants of human papillomavirus antigens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
CN1433428A (zh) * 2000-04-05 2003-07-30 冲击诊断公司 辨别人乳头瘤病毒的免疫学方法
PT1553966E (pt) * 2002-10-03 2012-10-22 Wyeth Corp Péptidos de fusão que compreendem os polipéptidos e7 e e6 do vírus do papiloma humano e as composições imunogénicas dos mesmos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004557A (en) * 1994-12-20 1999-12-21 Csl Limited Variants of human papillomavirus antigens

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Virology, Vol.70:2, pp.683-688 (1996.02.28.) *
Vaccine, Vol.14:16, pp.1485-1494 (1996.11.30.) *

Also Published As

Publication number Publication date
WO2004030636A3 (en) 2005-02-24
ZA200502618B (en) 2008-10-29
MXPA05003395A (es) 2005-06-22
EP1553966B1 (en) 2012-08-01
CN1720060A (zh) 2006-01-11
DK1553966T3 (da) 2012-09-17
US7223408B2 (en) 2007-05-29
JP2006501825A (ja) 2006-01-19
US7378099B2 (en) 2008-05-27
US20070275003A1 (en) 2007-11-29
AU2003282731B2 (en) 2009-01-08
WO2004030636A2 (en) 2004-04-15
CA2499837C (en) 2013-12-03
JP2010279386A (ja) 2010-12-16
CA2499837A1 (en) 2004-04-15
NZ556544A (en) 2008-11-28
BR0314529A (pt) 2005-08-09
US20060014926A1 (en) 2006-01-19
ES2391451T3 (es) 2012-11-26
JP4755422B2 (ja) 2011-08-24
EP1553966A4 (en) 2008-04-16
KR20050053732A (ko) 2005-06-08
AU2003282731A1 (en) 2004-04-23
PT1553966E (pt) 2012-10-22
JP5398665B2 (ja) 2014-01-29
CO5700784A2 (es) 2006-11-30
EP1553966A2 (en) 2005-07-20
CN1720060B (zh) 2011-12-14

Similar Documents

Publication Publication Date Title
KR101145190B1 (ko) 사람 파필로마바이러스 폴리펩타이드 및 면역원성 조성물
AU2021232660B2 (en) HPV vaccines
AU784605B2 (en) Chimeric immunogenic compositions and nucleic acids encoding them
US7318928B2 (en) Molecular vaccine linking intercellular spreading protein to an antigen
Cassetti et al. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes
Cornelison Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment
ES2634256T3 (es) Composiciones innovadoras y usos de las mismas
Zhou et al. Efficient expression of modified human papillomavirus 16 E6/E7 fusion protein and the antitumor efficacy in a mouse model
HK40082300A (en) Hpv vaccines

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050401

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20081002

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20101020

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20110921

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20120419

FPAY Annual fee payment
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20120504

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20120507

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20150330

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20160330

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20160330

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20170330

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20170330

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20180329

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20180329

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20190327

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20190327

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20200324

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20210329

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20220325

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20230327

Start annual number: 12

End annual number: 12

PC1801 Expiration of term

Termination date: 20240402

Termination category: Expiration of duration